title: Chitosan-starch nanocomposite particles as a drug carrier for the delivery of bis-desmethoxy curcumin analog.
abstract: The conventional drug delivery system has serious limitations such as lack of target specificity, altered effects and diminished potency. These limitations can be overcome by using biocompatible polymer as an effective drug delivery system. In this study, bis-demethoxy curcumin analog loaded Chitosan-starch (BDMCA-CS) nanocomposite particles were developed using different ratios of Chitosan and starch (3:1, 1:1 & 1:3) by ionic gelation method. The entrapment efficiency and drug loading capacity were found to be high for the formulation with the ratio 3:1 of BDMCA:CS. Physical characterization of the nanocomposite particles was determined using DLS and FTIR. The morphology of the BDMCA-CS nanocomposite particles were found to be spherical and regular by SEM analysis. In-vitro drug release profile of the BDMCA-CS nanocomposite particles showed a very slow and sustained diffusion controlled release of the drug. The cancer cells targeting ability of the BDMCA-CS nanocomposite particles were confirmed by performing MTT assay on MCF-7 breast cancer cell lines and VERO cell lines.
authors.affiliation: Centre for Nanoscience and Technology, A.C. Tech Campus, Anna University, Chennai 600025, Tamil Nadu, India. Electronic address: chindu14@gmail.com.
authors.forename: Sindhuja Bala
authors.initials: SB
authors.lastname: Subramanian
authors.affiliation: Centre for Nanoscience and Technology, A.C. Tech Campus, Anna University, Chennai 600025, Tamil Nadu, India. Electronic address: fdapharma@gmail.com.
authors.forename: Arul Prakash
authors.initials: AP
authors.lastname: Francis
authors.affiliation: Centre for Nanoscience and Technology, A.C. Tech Campus, Anna University, Chennai 600025, Tamil Nadu, India. Electronic address: tdevasenabio@gmail.com.
authors.forename: Thiyagarajan
authors.initials: T
authors.lastname: Devasena
mesh_terms: D000818:Animals; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D048271:Chitosan / Q000008:administration & dosage* / Q000737:chemistry; D002522:Chlorocebus aethiops; D003474:Curcumin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D036381:Diarylheptanoids; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D061986:MCF-7 Cells; D053761:Nanocomposites / Q000008:administration & dosage* / Q000737:chemistry; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D013213:Starch / Q000008:administration & dosage* / Q000737:chemistry; D014709:Vero Cells
chemical_list: D036381:Diarylheptanoids; D004337:Drug Carriers; D013213:Starch; D048271:Chitosan; D003474:Curcumin; C050229:demethoxycurcumin
keywords: BDMCA; Chitosan; Drug delivery; MTT assay; Nanocomposite; Starch